Frontiers in Endocrinology (Nov 2021)
Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
- Linda Wu,
- Linda Wu,
- Linda Wu,
- Linda Wu,
- Venessa H. M. Tsang,
- Venessa H. M. Tsang,
- Sarah C. Sasson,
- Sarah C. Sasson,
- Sarah C. Sasson,
- Alexander M. Menzies,
- Alexander M. Menzies,
- Alexander M. Menzies,
- Matteo S. Carlino,
- Matteo S. Carlino,
- Matteo S. Carlino,
- David A. Brown,
- David A. Brown,
- David A. Brown,
- David A. Brown,
- Roderick Clifton-Bligh,
- Roderick Clifton-Bligh,
- Jenny E. Gunton,
- Jenny E. Gunton,
- Jenny E. Gunton
Affiliations
- Linda Wu
- Centre for Diabetes, Obesity and Endocrinology, The Westmead Institute for Medical Research, Sydney, NSW, Australia
- Linda Wu
- Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW, Australia
- Linda Wu
- Department of Endocrinology, Westmead Hospital, Sydney, NSW, Australia
- Linda Wu
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
- Venessa H. M. Tsang
- Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW, Australia
- Venessa H. M. Tsang
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
- Sarah C. Sasson
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
- Sarah C. Sasson
- Department of Immunology, Westmead Hospital, Sydney, NSW, Australia
- Sarah C. Sasson
- NSW Health Pathology, Institute of Clinical Pathology and Medical Research (ICPMR), Sydney, NSW, Australia
- Alexander M. Menzies
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
- Alexander M. Menzies
- Department of Medical Oncology, Royal North Shore Hospital, Sydney, NSW, Australia
- Alexander M. Menzies
- Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
- Matteo S. Carlino
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
- Matteo S. Carlino
- Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia
- Matteo S. Carlino
- Department of Medical Oncology, Westmead Hospital, Sydney, NSW, Australia
- David A. Brown
- Centre for Diabetes, Obesity and Endocrinology, The Westmead Institute for Medical Research, Sydney, NSW, Australia
- David A. Brown
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
- David A. Brown
- Department of Immunology, Westmead Hospital, Sydney, NSW, Australia
- David A. Brown
- NSW Health Pathology, Institute of Clinical Pathology and Medical Research (ICPMR), Sydney, NSW, Australia
- Roderick Clifton-Bligh
- Department of Endocrinology, Royal North Shore Hospital, Sydney, NSW, Australia
- Roderick Clifton-Bligh
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
- Jenny E. Gunton
- Centre for Diabetes, Obesity and Endocrinology, The Westmead Institute for Medical Research, Sydney, NSW, Australia
- Jenny E. Gunton
- Department of Endocrinology, Westmead Hospital, Sydney, NSW, Australia
- Jenny E. Gunton
- Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia
- DOI
- https://doi.org/10.3389/fendo.2021.764138
- Journal volume & issue
-
Vol. 12
Abstract
Immune checkpoint inhibitors have transformed the landscape of oncological therapy, but at the price of a new array of immune related adverse events. Among these is β-cell failure, leading to checkpoint inhibitor-related autoimmune diabetes (CIADM) which entails substantial long-term morbidity. As our understanding of this novel disease grows, parallels and differences between CIADM and classic type 1 diabetes (T1D) may provide insights into the development of diabetes and identify novel potential therapeutic strategies. In this review, we outline the knowledge across the disciplines of endocrinology, oncology and immunology regarding the pathogenesis of CIADM and identify possible management strategies.
Keywords
- immune checkpoint inhibitor (ICI)
- diabetes mellitus
- type 1 diabetes
- immune related adverse events
- immunotherapy
